Search for: "C Lillie"
Results 41 - 60
of 440
Sorted by Relevance
|
Sort by Date
17 Jan 2007, 5:52 am
Whatever the legal merits of Lilly's claims against Mr. [read post]
24 Jul 2015, 7:27 am
The employee appealed, arguing that the Lilly Ledbetter Fair Pay Act of 2009 applied to and revived the otherwise time-barred claim. [read post]
2 Jun 2017, 8:47 am
Com. 11 January 2017, No 15-15750, Bull: Monsieur X c. [read post]
2 Nov 2008, 3:38 pm
June 15, 2006 – Danielle C. [read post]
14 Jul 2014, 11:28 am
These patents cover a method of using Effient products for which Lilly claims an exclusively license. [read post]
27 Sep 2017, 3:29 am
The UK judgment considered whether the Actavis generic pemetrexed products, which used (a) pemetrexed diacid, (b) pemetrexed ditromethamine, or (c) pemetrexed dipotassium, directly infringed the UK, Italian, Spanish or French designations of the patent claims, which specify pemetrexed disodium. [read post]
11 Dec 2023, 7:43 am
” citing Eli Lilly and Co. v. [read post]
4 Mar 2019, 8:44 am
Ixekizumab was developed by Lilly after the priority date of the 822 patent and is authorised for the treatment of psoriasis. [read post]
16 Sep 2019, 2:10 am
Genentech (C-239/19) of 5 September 2019. [read post]
20 Aug 2019, 2:05 am
ITC and Eli Lilly and Co. v. [read post]
17 Jul 2011, 9:55 am
There are two appeals in the Supreme Court beginning with Human Genome Sciences Inc v Eli Lilly and Company to be heard on Monday 18 to Wednesday 20 July 2011 by Lords Hope, Walker, Neuberger, Collins and Clarke. [read post]
5 Sep 2011, 9:27 pm
Lilly, 2011 U.S. [read post]
10 Feb 2014, 10:00 am
When Cadieux came into Proffitt’s room at 1:20 a.m. and saw the change, she immediately asked the nurses to notify their supervisor and get an anesthesiologist so an emergency C-section could be performed. [read post]
17 Oct 2007, 4:16 am
Duffy"Making Sense of KSR and Other Recent Patent Cases" by Harold C. [read post]
2 Nov 2011, 5:40 am
Supreme Court Rainy Sky SA & Orsd v Kookmin Bank [2011] UKSC 50 (2 November 2011) Human Genome Sciences Inc v Eli Lilly and Company [2011] UKSC 51 (2 November 2011) Court of Appeal (Civil Division) MD (Angola) & Ors, R (on the application of) v Secretary of State for the Home Department & Anor [2011] EWCA Civ 1238 (01 November 2011) Mitu v London Borough of Camden [2011] EWCA civ 1249 (01 November 2011) Williams v University of Birmingham & Anor [2011] EWCA Civ 1242 (28… [read post]
9 May 2017, 4:42 am
Subsequently, the CJEU held in Case C-493/12 Eli Lilly & Co Ltd v Human Genome Sciences Inc [EU: C:2013:835] that Article 3(a) must be interpreted as meaning that it was not necessary for the active ingredient to be identified in the claim by means of a structural formula. [read post]
18 May 2020, 1:30 pm
Andrea C. [read post]
14 Apr 2010, 8:18 am
Eli Lilly and Company, 2008-1248 (Mar. 22, 2010). [read post]
22 Feb 2021, 12:25 pm
Among the blue-chip firms that participated in the 2021 survey were American Express, Anthem, Bank of America, Bristol-Myer Squibb, Capital One, Cigna, CVS Health, Eli Lilly, Glaxo Smith Kline, JP Morgan Chase, Liberty Mutual, Mastercard, McDonalds, Merck, Pfizer, Sanofi, Starbucks, United Health, VISA, and Walmart. [read post]
31 Jan 2018, 10:05 pm
Article 3(a): a spectrum of specificity The Court of Appeal reviewed the case law of the CJEU and pending references, focussing on Case C-322/10 Medeva BV v Comptroller-General of Patents, Designs and Trade Marks and Case C-493/12 Eli Lilly & Co Ltd v Human Genome Sciences Inc. [read post]
